Follow Us:

social twitter box white 32 social facebook box blue 32social linkedin box blue 32ISN Blog

Wednesday, 17 June 2015 20:44

Less of the same—PA21 can reduce pill burden in patients with hyperphosphataemia

By  Tim Geach
Rate this item
(0 votes)

Patients with chronic kidney disease (CKD) often develop hyperphosphataemia, which can lead to bone mineral disease, cardiovascular problems and, eventually, death. Although phosphate-binding drugs are used to control serum phosphorous levels, patients are often required to take a high number of pills—which can reduce patient adherence. Indeed, reducing dependence on medication can not only improve quality of life, but also increase the likelihood of a patient continuing their treatment. A phase III trial, reported in Kidney International, now shows that the phosphate binder PA21 (sucroferric oxyhydroxide) is equally effective as the commonly used sevelamer carbonate for maintaining phosphate levels, but crucially does so with fewer pills.

 Author: Tim Geach

Reference: Nature Reviews Nephrology 10, 297 (2014) doi:10.1038/nrneph.2014.62; Published online 08 April 2014

Additional Info

  • Language: English
  • Contains Audio: No
  • Content Type: Articles
  • Year: 2015
  • Members Only: No
Read 301 times

Leave your comments

Post comment as a guest

Your comments are subject to administrator's moderation.
terms and condition.
  • No comments found

compact red

Global Operations Center

Rue des Fabriques 1
1000 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact


Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact